Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 6, 2015, Pages E535-E544

  Martinussen, Christoffer ^a,b   Bojsen Møller, Kirstine N ^a,b   Dirksen, Carsten ^a,b   Jacobsen, Siv H ^a,b   Jørgensen, Nils B ^a,b   Kristiansen, Viggo B ^a   Holst, Jens J ^b,c   Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

First phase insulin secretion; Glucose effectiveness; Insulin sensitivity; Type 2 diabetes; cell function

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLUCOSE; INSULIN; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY WEIGHT; CELL FUNCTION; COMORBIDITY; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ROUX EN Y GASTRIC BYPASS; STOMACH BYPASS; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REHABILITATION; SECRETION (PROCESS);

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FASTING; GASTRIC BYPASS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MIDDLE AGED; OBESITY; POSTOPERATIVE PERIOD;

EID: 84930897612     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00506.2014     Document Type: Article

References (56)

1. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790-800, 1987.
2. Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19: 1018-1030, 1996.
3. Bojsen-Møller KN, Dirksen C, Jørgensen NB, Jacobsen SH, Hansen DL, Worm D, Naver L, Kristiansen VB, Holst JJ, Madsbad S. Increased hepatic insulin clearance after Roux-en-Y gastric bypass. J Clin Endocrinol Metab 98: E1066-1071, 2013.
4. Bojsen-Møller KN, Dirksen C, Jørgensen NB, Jacobsen SH, Serup AK, Albers PH, Hansen DL, Worm D, Naver L, Kristiansen VB, Wojtaszewski JFP, Kiens B, Holst JJ, Richter EA, Madsbad S. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63: 1725-1737, 2014.
5. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5: 1003-1015, 2003.
6. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulindependent diabetes. Diabetes 37: 736-744, 1988.
7. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42: 222-229, 1976.
8. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 49: 782-788, 2000.
9. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110, 2003.
10. Camastra S, Gastaldelli A, Mari A, Bonuccelli S, Scartabelli G, Frascerra S, Baldi S, Nannipieri M, Rebelos E, Anselmino M, Muscelli E, Ferrannini E. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 54: 2093-2102, 2011.
11. Castillo MJ, Scheen AJ, Letiexhe MR, Lefèbvre PJ. How to measure insulin clearance. Diabetes Metab Rev 10: 119-150, 1994.
12. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31: 1927-1932, 2008.
13. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, Butler P, Rizza R. Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293: E1-E15, 2007.
14. Defronzo Banting Lecture RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795, 2009. 14a.Del Prato S, Matsuda M, Simonson DC, Groop LC, Sheehan P, Leonetti F, Bonadonna RC, DeFronzo RA. Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. Diabetologia 40: 687-697, 1997.
15. Dirksen C, Bojsen-Møller KN, Jørgensen NB, Jacobsen SH, Kristiansen VB, Naver LS, Hansen DL, Worm D, Holst JJ, Madsbad S. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 56: 2679-2687, 2013.
16. Dirksen C, Damgaard M, Bojsen-Møller KN, Jørgensen NB, Kielgast U, Jacobsen SH, Naver LS, Worm D, Holst JJ, Madsbad S, Hansen DL, Madsen JL. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil 25: 346-e255, 2013.
17. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90: 5991-5997, 2005.
18. García-Fuentes E, García-Almeida JM, García-Arnés J, Rivas-Marín J, Gallego-Perales JL, González-Jiménez B, Cardona I, García-Serrano S, Garriga MJ, Gonzalo M, De Adana MSR, Soriguer F. Morbidly obese individuals with impaired fasting glucose have a specific pattern of insulin secretion and sensitivity: effect of weight loss after bariatric surgery. Obes Surg 16: 1179-1188, 2006.
19. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34: 222-234, 1985.
20. Gleason CE, Gonzalez M, Harmon JS, Robertson RP. Determinants of glucose toxicity and its reversibility in the pancreatic islet β-cell line, HIT-T15. Am J Physiol Endocrinol Metab 279: E997-E1002, 2000.
21. Godsland IF, Walton C. Maximizing the success rate of minimal model insulin sensitivity measurement in humans: the importance of basal glucose levels. Clin Sci (Lond) 101: 1-9, 2001.
22. Hawkins M, Gabriely I, Wozniak R, Reddy K, Rossetti L, Shamoon H. Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes 51: 2179-2189, 2002.
23. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50: 253-264, 1996.
24. Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52: 199-207, 2009.
25. Jackness C, Karmally W, Febres G, Conwell IM, Ahmed L, Bessler M, McMahon DJ, Korner J. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell function in type 2 diabetic patients. Diabetes 62: 3027-3032, 2013.
26. Jacobsen SH, Bojsen-Møller KN, Dirksen C, Jørgensen NB, Clausen TR, Wulff BS, Kristiansen VB, Worm D, Hansen DL, Holst JJ, van Hall G, Madsbad S. Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. Diabetologia 56: 2250-2254, 2013.
27. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 22: 1084-1096, 2012.
28. Jensen DH, Aaboe K, Henriksen JE, Vølund A, Holst JJ, Madsbad S, Krarup T. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia 55: 1406-1416, 2012.
29. Jiménez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36: 2062-2069, 2013.
30. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, Kristiansen VB, Naver L, Madsbad S, Holst JJ. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62: 3044-3052, 2013.
31. Jørgensen NB, Jacobsen SH, Dirksen C, Bojsen-Møller KN, Naver L, Hvolris L, Clausen TR, Wulff BS, Worm D, Lindqvist Hansen D, Madsbad S, Holst JJ. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 303: E122-E131, 2012.
32. Kahn SE, Klaff LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ, Porte D. Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab 71: 994-1002, 1990.
33. Kashyap SR, Daud S, Kelly KR, Gastaldelli a Win H, Brethauer S, Kirwan JP, Schauer PR. Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) 34: 462-471, 2010.
34. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 2479-2485, 2008.
35. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54: 2506-2514, 2011.
36. Lin E, Liang Z, Frediani J, Davis SS, Sweeney JF, Ziegler TR, Phillips LS, Gletsu-Miller N. Improvement in β-cell function in patients with normal and hyperglycemia following Roux-en-Y gastric bypass surgery. Am J Physiol Endocrinol Metab 299: E706-E712, 2010.
37. Mari A. Assessment of insulin sensitivity with minimal model: role of model assumptions. Am J Physiol Endocrinol Metab 272: E925-E934, 1997.
38. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340: 925-929, 1992.
39. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
40. Meier S, Hücking K, Ritzel R, Holst JJ, Schmiegel WH, Nauck MA. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. Horm Metab Res 35: 551-556, 2003.
41. Morínigo R, Lacy AM, Casamitjana R, Delgado S, Gomis R, Vidal J. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 16: 1594-1601, 2006.
42. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 17: 305-322, 2003.
43. Plum L, Ahmed L, Febres G, Bessler M, Inabnet W, Kunreuther E, McMahon DJ, Korner J. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring) 19: 2149-2157, 2011.
44. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222: 339-350; discussion 350-352, 1995.
45. Porte Banting lecture 1990 D. Beta-cells in type II diabetes mellitus. Diabetes 40: 166-180, 1991.
46. Pournaras DJ, Aasheim ET, Søvik TT, Andrews R, Mahon D, Welbourn R, Olbers T, le Roux CW. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 99: 100-103, 2012.
47. Reeda M, Pories WJ, Chapman W, Pender J, Bowden R, Barakat H, Gavin TP, Green T, Tapscott E, Zheng D, Shankley N, Yieh L, Polidori D, Piccoli SP, Brenner-Gati L, Dohm GL. Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes. J Clin Endocrinol Metab 96: 2525-2531, 2011.
48. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA Trial. Diabetes Care 37: 3270-3278, 2014.
49. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27: 1028-1032, 2004.
50. Salehi M, Gastaldelli A, D'Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 146: 669-680; e2, 2014.
51. Salinari S, Bertuzzi A, Guidone C, Previti E, Rubino F, Mingrone G. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg 257: 462-468, 2013.
52. Tobin BL, Finegood DT. Reduced insulin secretion by repeated low doses of STZ impairs glucose effectiveness but does not induce insulin resistance in dogs. Diabetes 42: 474-483, 1993.
53. Vetter ML, Wadden TA, Teff KL, Khan Z, Carvajal R, Ritter S, Moore RH, Chittams JL, Iagnocco A, Murayama K, Korus G, Williams NN, Rickels MR. GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison to intensive lifestyle modification. Diabetes 64: 434-446, 2014.
54. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
55. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760, 2008.
56. Wewer Albrechtsen NJ, Hartmann B, Veedfald S, Windeløv JA, Plamboeck A, Bojsen-Møller KN, Idorn T, Feldt-Rasmussen B, Knop FK, Vilsbøll T, Madsbad S, Deacon CF, Holst JJ. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57: 1919-1926, 2014.